A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help with weight.

Who can join

Adults 18+, have obesity, BMI 30+.

What you take

cagrilintide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The study runs about 18 months.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events.

Primary condition: Obesity. Also studied in: Overweight.

Who can join, in detail

Key inclusion criteria

• Male or female (sex at birth)
• Age 18 years or above at the time of signing the informed consent
• History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
• Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
• Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m^2)

Key exclusion criteria

• Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
• Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
• History of type 1 or type 2 diabetes
• Glycated haemoglobin (HbA1c) >= 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening
• Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening

Where this study is enrolling

This trial has 11 US sites across 6 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2026-05-29. Expected completion: 2027-11-19. Last updated on ClinicalTrials.gov: 2026-05-26.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact